Rapamycin preferentially inhibits human IL-5+ TH2-cell proliferation via an mTORC1/S6 kinase-1–dependent pathway - 27/09/17
Doi : 10.1016/j.jaci.2016.10.029
Yuzhi Yin, MD, PhD a, Alyssa Mitson-Salazar, BS a, Daniel L. Wansley, PhD a, Satya P. Singh, PhD b, Calman Prussin, MD a 
a Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
b Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md
| This research was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases. |
|
| Disclosure of potential conflict of interest: A. Miltson-Salazar, D. L. Wansley, and S. P. Singh receive grant support from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH). C. Prussin receives grant support from the NIAID and the NIH and serves on the board for the American Board of Allergy and Immunology. Y. Yin declares no relevant conflicts of interest. |
© 2016
Publié par Elsevier Masson SAS.
Vol 139 - N° 5
P. 1701 - mai 2017 Retour au numéro
Article précédent
- Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition
- Scott W. Canna, Charlotte Girard, Louise Malle, Adriana de Jesus, Neil Romberg, Judith Kelsen, Lea F. Surrey, Pierre Russo, Andrew Sleight, Eduardo Schiffrin, Cem Gabay, Raphaela Goldbach-Mansky, Edward M. Behrens
- Molecular engineering of a therapeutic antibody for Blo t 5–induced allergic asthma
- J.H. Sherlynn Chan, Yen Leong Chua, Hong Yong Peh, Vojislav Jovanovic, Nicholas R.J. Gascoigne, W. S. Fred Wong, Fook Tim Chew, Brendon J. Hanson, David M. Kemeny, Paul A. MacAry
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?